Return to homepagePandemic Pact

Assess the Efficacy of Combination Treatment with ACE2-R Blocker and TMPRSS2

  • Funded by Vancouver Coastal Health Research Institute
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Vancouver Coastal Health Research Institute

  • Principal Investigator

    Dr. Isabella Tai

  • Research Location

    Canada

  • Lead Research Institution

    University of British Columbia Department of Medicine

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The global scale and high infection rate of the COVID-19 pandemic has intensified the need to find safe and effective treatments to combat the virus. Research has identified potential therapeutic targets for further testing that could block the entry of SARS-CoV-2 into human cells and reduce infection rates. This research project will involve testing a dual combination therapy comprised of an ACE2 receptor blocker and a TMPRSS2 inhibitor to determine their potential in reducing the symptoms many COVID-19 positive patients experience. Dr. Tai hypothesizes that the combination therapy will have better efficacy than a single therapy in reducing the severity of COVID-19 infections and preventing the virus from entering and infecting cells. This could lead to better, faster recovery rates and fewer hospital and Intensive Care Unit admissions related to COVID-19.